Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 620 Lesher Pl LANSING MI 48912-1509 |
Tel: | N/A |
Website: | https://www.neogen.com |
IR: | See website |
Key People | ||
John Edward Adent President, Chief Executive Officer, Director | David Hartman Naemura Chief Financial Officer | Doug E. Jones Chief Operating Officer |
John Moylan Chief Accounting Officer, Vice President, Corporate Controller | Amy M. Rocklin Chief Legal & Compliance Officer | Steven J. Quinlan Vice President - Finance |
James Walter Vice President - Global Operations | Jason Warren Lilly Vice President, Americas, Australia and New Zealand |
Business Overview |
Neogen Corporation is engaged in developing, manufacturing and marketing a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. Its Food Safety segment consists primarily of diagnostic test kits and complementary products sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns. Its Animal Safety segment is engaged in the development, manufacture, marketing, and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services for the worldwide animal safety market. |
Financial Overview |
For the nine months ended 29 February 2024, Neogen Corp revenues increased 18% to $687.4M. Net loss decreased 86% to $4M. Revenues reflect Food Safety segment increase of 29% to $488.4M, International segment increase of 23% to $338.6M, Domestic segment increase of 14% to $348.8M. Lower net loss reflects Food Safety segment income increase of 52% to $62.5M, Corporate and Eliminations segment loss decrease of 24% to $47.7M. |